<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04443660</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2019-01/SB-01</org_study_id>
    <nct_id>NCT04443660</nct_id>
  </id_info>
  <brief_title>Autophagy/Apoptosis Balance During Pregnancy</brief_title>
  <acronym>GROSSAUTOP</acronym>
  <official_title>Autophagy/Apoptosis Balance During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The object of this study is to assess the intra- and inter-individual variability of
      apoptosis and autophagy activities in women during pregnancy: 1 / in women with a normal
      pregnancy and 2 / in pregnant women particularly at risk of complications.

      The study investigators hypothesize that there would be an intra-trophoblastic dialogue
      between the mechanisms of autophagy and apoptosis, the promotion of one partially inhibiting
      the other. The increase in trophoblastic autophagy during pregnancy could thus constitute an
      anti-apoptosis defense phenomenon, the exhaustion of which would lead to cellular apoptosis
      and to pathogenic consequences when it devastates the syncytiotrophoblast.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Potential autophagy induction activity in all groups</measure>
    <time_frame>Day 0</time_frame>
    <description>Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential autophagy induction activity in all groups</measure>
    <time_frame>Month 1</time_frame>
    <description>Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential autophagy induction activity in all groups</measure>
    <time_frame>Month 2</time_frame>
    <description>Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential autophagy induction activity in all groups</measure>
    <time_frame>Month 3</time_frame>
    <description>Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential autophagy induction activity in all groups</measure>
    <time_frame>Month 4</time_frame>
    <description>Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential autophagy induction activity in all groups</measure>
    <time_frame>Month 5</time_frame>
    <description>Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Potential autophagy induction activity in all groups</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>Microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of autophagy inhibition per patient in all groups</measure>
    <time_frame>Day 0</time_frame>
    <description>Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of autophagy inhibition per patient in all groups</measure>
    <time_frame>Month 1</time_frame>
    <description>Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of autophagy inhibition per patient in all groups</measure>
    <time_frame>Month 2</time_frame>
    <description>Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of autophagy inhibition per patient in all groups</measure>
    <time_frame>Month 3</time_frame>
    <description>Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of autophagy inhibition per patient in all groups</measure>
    <time_frame>Month 4</time_frame>
    <description>Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of autophagy inhibition per patient in all groups</measure>
    <time_frame>Month 5</time_frame>
    <description>Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of autophagy inhibition per patient in all groups</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>Early/late; measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential apoptosis induction activity in all groups</measure>
    <time_frame>Day 0</time_frame>
    <description>% cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential apoptosis induction activity in all groups</measure>
    <time_frame>Month 1</time_frame>
    <description>% cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential apoptosis induction activity in all groups</measure>
    <time_frame>Month 2</time_frame>
    <description>% cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential apoptosis induction activity in all groups</measure>
    <time_frame>Month 3</time_frame>
    <description>% cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential apoptosis induction activity in all groups</measure>
    <time_frame>Month 4</time_frame>
    <description>% cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential apoptosis induction activity in all groups</measure>
    <time_frame>Month 5</time_frame>
    <description>% cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential apoptosis induction activity in all groups</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>% cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter- and intra-individual apoptosis/autophagy ratio in all groups</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter- and intra-individual apoptosis/autophagy ratio in all groups</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter- and intra-individual apoptosis/autophagy ratio in all groups</measure>
    <time_frame>Month 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter- and intra-individual apoptosis/autophagy ratio in all groups</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter- and intra-individual apoptosis/autophagy ratio in all groups</measure>
    <time_frame>Month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter- and intra-individual apoptosis/autophagy ratio in all groups</measure>
    <time_frame>Month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter- and intra-individual apoptosis/autophagy ratio in all groups</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autophagy kinetics between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autophagy kinetics between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autophagy kinetics between groups</measure>
    <time_frame>Month 2</time_frame>
    <description>measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autophagy kinetics between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autophagy kinetics between groups</measure>
    <time_frame>Month 4</time_frame>
    <description>measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autophagy kinetics between groups</measure>
    <time_frame>Month 5</time_frame>
    <description>measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autophagy kinetics between groups</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>measured by microtubule-associated protein 1A/1B-light chain 3 fluorescence ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoptosis kinetics between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>measured by % cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoptosis kinetics between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>measured by % cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoptosis kinetics between groups</measure>
    <time_frame>Month 2</time_frame>
    <description>measured by % cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoptosis kinetics between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>measured by % cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoptosis kinetics between groups</measure>
    <time_frame>Month 4</time_frame>
    <description>measured by % cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoptosis kinetics between groups</measure>
    <time_frame>Month 5</time_frame>
    <description>measured by % cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoptosis kinetics between groups</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>measured by % cells positive for Annexin V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental Growth Factor in each group</measure>
    <time_frame>Day 0</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental Growth Factor in each group</measure>
    <time_frame>Month 1</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental Growth Factor in each group</measure>
    <time_frame>Month 2</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental Growth Factor in each group</measure>
    <time_frame>Month 3</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental Growth Factor in each group</measure>
    <time_frame>Month 4</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental Growth Factor in each group</measure>
    <time_frame>Month 5</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental Growth Factor in each group</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble fms-like tyrosine kinase-1</measure>
    <time_frame>Day 0</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble fms-like tyrosine kinase-1</measure>
    <time_frame>Month 1</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble fms-like tyrosine kinase-1</measure>
    <time_frame>Month 2</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble fms-like tyrosine kinase-1</measure>
    <time_frame>Month 3</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble fms-like tyrosine kinase-1</measure>
    <time_frame>Month 4</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble fms-like tyrosine kinase-1</measure>
    <time_frame>Month 5</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble fms-like tyrosine kinase-1</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>pg/ml measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constitutive thrombophilia</measure>
    <time_frame>Day 0</time_frame>
    <description>presence/absence of the prothrombin gene or factor V Leiden mutation, protein S, C or antithrombin deficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquired thrombophilia</measure>
    <time_frame>Day 0</time_frame>
    <description>Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquired thrombophilia</measure>
    <time_frame>Month 1</time_frame>
    <description>Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquired thrombophilia</measure>
    <time_frame>Month 2</time_frame>
    <description>Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquired thrombophilia</measure>
    <time_frame>Month 3</time_frame>
    <description>Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquired thrombophilia</measure>
    <time_frame>Month 4</time_frame>
    <description>Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquired thrombophilia</measure>
    <time_frame>Month 5</time_frame>
    <description>Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquired thrombophilia</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>Presence/absence of anti-phospholipid antibodies (lupus anticoagulant and/or anti beta2-GP1 and/or anti-cardiolipid).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole blood count</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole blood count</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole blood count</measure>
    <time_frame>Month 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole blood count</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole blood count</measure>
    <time_frame>Month 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole blood count</measure>
    <time_frame>Month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole blood count</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Day 0</time_frame>
    <description>creatinemia, proteinuria / creatinuria ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Month 1</time_frame>
    <description>creatinemia, proteinuria / creatinuria ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Month 2</time_frame>
    <description>creatinemia, proteinuria / creatinuria ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Month 3</time_frame>
    <description>creatinemia, proteinuria / creatinuria ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Month 4</time_frame>
    <description>creatinemia, proteinuria / creatinuria ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Month 5</time_frame>
    <description>creatinemia, proteinuria / creatinuria ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>creatinemia, proteinuria / creatinuria ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin levels</measure>
    <time_frame>Day 0</time_frame>
    <description>D dimers and fibrin monomers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin levels</measure>
    <time_frame>Month 1</time_frame>
    <description>D dimers and fibrin monomers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin levels</measure>
    <time_frame>Month 2</time_frame>
    <description>D dimers and fibrin monomers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin levels</measure>
    <time_frame>Month 3</time_frame>
    <description>D dimers and fibrin monomers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin levels</measure>
    <time_frame>Month 4</time_frame>
    <description>D dimers and fibrin monomers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin levels</measure>
    <time_frame>Month 5</time_frame>
    <description>D dimers and fibrin monomers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrin levels</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>D dimers and fibrin monomers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Day 0</time_frame>
    <description>C-reactive protein level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Month 1</time_frame>
    <description>C-reactive protein level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Month 2</time_frame>
    <description>C-reactive protein level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Month 3</time_frame>
    <description>C-reactive protein level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Month 4</time_frame>
    <description>C-reactive protein level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Month 5</time_frame>
    <description>C-reactive protein level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>C-reactive protein level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time</measure>
    <time_frame>Day 0</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time</measure>
    <time_frame>Month 1</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time</measure>
    <time_frame>Month 2</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time</measure>
    <time_frame>Month 3</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time</measure>
    <time_frame>Month 4</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time</measure>
    <time_frame>Month 5</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>Day 0</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>Month 1</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>Month 2</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>Month 3</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>Month 4</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>Month 5</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen level</measure>
    <time_frame>Day 0</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen level</measure>
    <time_frame>Month 1</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen level</measure>
    <time_frame>Month 2</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen level</measure>
    <time_frame>Month 3</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen level</measure>
    <time_frame>Month 4</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen level</measure>
    <time_frame>Month 5</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen level</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation time</measure>
    <time_frame>Month 1</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation time</measure>
    <time_frame>Month 2</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation time</measure>
    <time_frame>Month 3</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation time</measure>
    <time_frame>Month 4</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation time</measure>
    <time_frame>Month 5</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation time</measure>
    <time_frame>Delivery plus or minus 2 weeks (Month 6)</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation time</measure>
    <time_frame>Day 0</time_frame>
    <description>seconds</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>without medical history or risk factors, with a normal pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>without medical history or risk factors, developing a pregnancy complication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>with risk of complication, having a normal pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <description>with a risk of complication, developing a pregnancy complication</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Blood samples taken to test levels of autophagy and apoptosis</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum and mononuclear blood cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All pregnant women followed at the Nîmes University Hospital for their pregnancy. Patients
        will be recruited among those consulting hospital gynecologists from the 3rd month of
        pregnancy but also through the circuit of specific gynecology-obstetrics consultations
        receiving in particular women with a history and / or risk factors for pathological
        pregnancy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients followed at the CHU Nîmes prior to 33 weeks gestation who give birth at the
             hospital

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient must be a member or beneficiary of a health insurance plan

        Exclusion Criteria:

          -  The subject is participating in a category 1 interventional study associated with a
             medication, or is in a period of exclusion determined by a previous study

          -  The subject refuses to sign the consent

          -  It is impossible to give the subject informed information

          -  The patient is under safeguard of justice or state guardianship

          -  Multiple pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie Bouvier</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvie Bouvier</last_name>
    <phone>04.66.68.32.11</phone>
    <email>sylvie.bouvier@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvie Bouvier</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe Gris</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eve Mousty</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Letouzey</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène Martin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Porte</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marine Commissaire</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erick Mercier</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Nouvellon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autophagy</keyword>
  <keyword>Apoptosis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

